Friday, April 12, 2019
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a new collaboration with Pandion Therapeutics, to apply its antibody optimization platform to the targeting arm of a bispecific antibody. Pandion Therapeutics is a biotechnology platform company developing therapeutics to achieve localized immunomodulation to treat autoimmune and inflammatory disease.
"Twist Bioscience, through its Biopharma division, has a highly differentiated capability to optimize antibodies for many attributes including affinity, expression, solubility, half-life, immunogenicity, druggability and processability,” said Anthony Coyle, Ph.D., co-founder and CEO of Pandion. “We look forward to this initial project on a key therapeutic target that may offer hope for patients in need of new treatment options.”
“By approaching autoimmune and inflammatory disease through antibody therapeutics acting locally at the disease site, Pandion is working to change the trajectory of treatment,” commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Using our state-of-the-art antibody optimization platform, we look forward to partnering with Pandion to provide enhanced antibodies ideally suited to the human body to potentially improve patient outcomes.”
